ImmunoKey Launches Crowdcube Campaign to Accelerate Next-Gen CAR T-Cell Therapies

Bionow member ImmunoKey has officially launched an investment round on Crowdcube, inviting the life sciences community and private investors to support the development of their pioneering immune therapy platform, CARKey™.

Based at Alderley Park, ImmunoKey is an early-stage biotech company tackling the critical barriers that have historically limited the success of CAR T-cell therapy in treating solid tumours. With a Patent-filed design, the platform attacks 3 cancer targets, whilst safeguarding healthy tissue from toxicity.

The company was founded by a proven team with a track record of success, led by the biotech experts who conducted the first-ever CAR T-cell therapy trials in the UK. This team is now leveraging their deep clinical experience to fast-track these next-generation therapies from the lab to the patient.

ImmunoKey’s primary focus is ovarian cancer. A disease characterised by a high unmet medical need and a lack of effective treatment options. The funds raised through this campaign will support vital pre-clinical studies, moving the CARKey™ platform closer to clinical application.

Building on years of experience in generating and advancing T-cell therapies, ImmunoKey is warmly inviting the wider network to join their journey at this pivotal stage. Together, they aim to develop the "keys" to unlock the next generation of cancer cures.

How to Get Involved

The campaign is now live on Crowdcube, offering a unique opportunity to become a shareholder in a UK biotech innovator.

Tax Efficiency: ImmunoKey is EIS eligible, offering potential tax reliefs for qualifying UK taxpayers.

View the Pitch: ImmunoKey on Crowdcube

Learn More: www.immunokey.co.uk

Disclaimer: Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.pivotal